-
1
-
-
79958043675
-
-
Bethesda, MD: National Cancer Institute [cited 2013]. based on November 2012 SEER data submission, posted to the SEER web site. Available from
-
SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute; 2013 [cited 2013]. based on November 2012 SEER data submission, posted to the SEER web site. Available from: http://seer.cancer.gov/csr/1975-2010/.
-
(2013)
SEER Cancer Statistics Review, 1975-2010
-
-
-
2
-
-
84875419612
-
-
Version 2 Epithelial Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer 2013 [cited 2013]. Available from
-
Network NCC. NCCN Guidelines Version 2.2013; Epithelial Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer 2013 [cited 2013]. Available from: http://www.nccn.org/professionals/physician-gls/pdf/ovarian.pdf.
-
(2013)
NCCN Guidelines
-
-
-
3
-
-
84874644333
-
Ovarian cancer stem cells: A new target for cancer therapy
-
Zhan Q, Wang C, Ngai S. Ovarian cancer stem cells: a new target for cancer therapy. BioMed Res Int 2013;2013:916819.
-
(2013)
BioMed Res Int
, vol.2013
-
-
Zhan, Q.1
Wang, C.2
Ngai, S.3
-
4
-
-
49249091523
-
Identification and characterization of ovarian cancer-initiating cells from primary human tumors
-
Zhang S, Balch C, Chan M.W., Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008;68:4311-20.
-
(2008)
Cancer Res
, vol.68
, pp. 4311-4320
-
-
Zhang, S.1
Balch, C.2
Chan, M.W.3
Lai, H.C.4
Matei, D.5
Schilder, J.M.6
-
5
-
-
77952240931
-
+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells
-
+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010;29:2672-80.
-
(2010)
Oncogene
, vol.29
, pp. 2672-2680
-
-
Gao, M.Q.1
Choi, Y.P.2
Kang, S.3
Youn, J.H.4
Cho, N.H.5
-
7
-
-
79961119901
-
Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome
-
Luo L, Zeng J, Liang B., Zhao Z, Sun L, Cao D., et al. Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome. Exp Mol Pathol 2011;91:596-602.
-
(2011)
Exp Mol Pathol
, vol.91
, pp. 596-602
-
-
Luo, L.1
Zeng, J.2
Liang, B.3
Zhao, Z.4
Sun, L.5
Cao, D.6
-
9
-
-
0032995287
-
The prognostic significance of angiogenesis in epithelial ovarian carcinoma
-
Alvarez AA, Krigman HR, Whitaker R.S., Dodge RK, Rodriguez GC. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 1999;5:587-91.
-
(1999)
Clin Cancer Res
, vol.5
, pp. 587-591
-
-
Alvarez, A.A.1
Krigman, H.R.2
Whitaker, R.S.3
Dodge, R.K.4
Rodriguez, G.C.5
-
10
-
-
66349096698
-
VEGF - A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection
-
Engels K, du Bois A, Harter P, Fisseler-Eckhoff A, Kommoss F., Stauber R, et al. VEGF - A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection. J Clin Pathol 2009;62:448-54.
-
(2009)
J Clin Pathol
, vol.62
, pp. 448-454
-
-
Engels, K.1
Du Bois, A.2
Harter, P.3
Fisseler-Eckhoff, A.4
Kommoss, F.5
Stauber, R.6
-
11
-
-
0028834106
-
Pathogenesis of ascites tumor growth: Vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation
-
Nagy JA, Masse EM, Herzberg K.T., Meyers MS, Yeo KT, Yeo TK, et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995;55:360-8.
-
(1995)
Cancer Res
, vol.55
, pp. 360-368
-
-
Nagy, J.A.1
Masse, E.M.2
Herzberg, K.T.3
Meyers, M.S.4
Yeo, K.T.5
Yeo, T.K.6
-
12
-
-
0028857418
-
Pathogenesis of ascites tumor growth: Angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining
-
Nagy JA, Morgan ES, Herzberg K.T., Manseau EJ, Dvorak AM, Dvorak HF. Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining. Cancer Res 1995;55:376-85.
-
(1995)
Cancer Res
, vol.55
, pp. 376-385
-
-
Nagy, J.A.1
Morgan, E.S.2
Herzberg, K.T.3
Manseau, E.J.4
Dvorak, A.M.5
Dvorak, H.F.6
-
13
-
-
79952818552
-
Overview of anti-angiogenic agents in development for ovarian cancer
-
Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011;121:230-8.
-
(2011)
Gynecol Oncol
, vol.121
, pp. 230-238
-
-
Burger, R.A.1
-
14
-
-
84859156536
-
Targeting angiogenesis in ovarian cancer
-
Schmitt J, Matei D. Targeting angiogenesis in ovarian cancer. Cancer Treat Rev 2012;38:272-83.
-
(2012)
Cancer Treat Rev
, vol.38
, pp. 272-283
-
-
Schmitt, J.1
Matei, D.2
-
15
-
-
77953616808
-
Impact of tumor microenvironment on oncolytic viral therapy
-
Wojton J, Kaur B. Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev 2010;21:127-34.
-
(2010)
Cytokine Growth Factor Rev
, vol.21
, pp. 127-134
-
-
Wojton, J.1
Kaur, B.2
-
17
-
-
84863011273
-
Antitumor efficacy of 34.5ENVE: A transcriptionally retargeted and "Vstat120"-expressing oncolytic virus
-
Yoo JY, Haseley A, Bratasz A., Chiocca EA, Zhang J, Powell K, et al Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. Mol Ther 2012;20: 287-97.
-
(2012)
Mol Ther
, vol.20
, pp. 287-297
-
-
Yoo, J.Y.1
Haseley, A.2
Bratasz, A.3
Chiocca, E.A.4
Zhang, J.5
Powell, K.6
-
18
-
-
76349108532
-
Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1
-
Hardcastle J, Kurozumi K, Dmitrieva N., Sayers MP, Ahmad S, Waterman P, et al. Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther 2010;18:285-94.
-
(2010)
Mol Ther
, vol.18
, pp. 285-294
-
-
Hardcastle, J.1
Kurozumi, K.2
Dmitrieva, N.3
Sayers, M.P.4
Ahmad, S.5
Waterman, P.6
-
19
-
-
19944379133
-
Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor
-
Kaur B, Brat DJ, Devi N.S., Van Meir EG. Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene 2005;24:3632-42.
-
(2005)
Oncogene
, vol.24
, pp. 3632-3642
-
-
Kaur, B.1
Brat, D.J.2
Devi, N.S.3
Van Meir, E.G.4
-
20
-
-
33750700474
-
The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer
-
Hasegawa K, Nakamura T, Harvey M., Ikeda Y, Oberg A, Figini M., et al. The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res 2006;12(20 Pt 1):6170-8.
-
(2006)
Clin Cancer Res
, vol.12
, Issue.20
, pp. 6170-6178
-
-
Hasegawa, K.1
Nakamura, T.2
Harvey, M.3
Ikeda, Y.4
Oberg, A.5
Figini, M.6
-
21
-
-
0032486317
-
Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor
-
Geraghty RJ, Krummenacher C, Cohen G.H., Eisenberg RJ, Spear PG. Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science 1998;280: 1618-20.
-
(1998)
Science
, vol.280
, pp. 1618-1620
-
-
Geraghty, R.J.1
Krummenacher, C.2
Cohen, G.H.3
Eisenberg, R.J.4
Spear, P.G.5
-
22
-
-
0032551272
-
A cell surface protein with herpesvirus entry activity (HveB) confers susceptibility to infection by mutants of herpes simplex virus type 1, herpes simplex virus type 2, and pseudorabies virus
-
Warner MS, Geraghty RJ, Martinez W.M., Montgomery RI, Whitbeck JC, Xu R, et al. A cell surface protein with herpesvirus entry activity (HveB) confers susceptibility to infection by mutants of herpes simplex virus type 1, herpes simplex virus type 2, and pseudorabies virus. Virology 1998;246:179-89.
-
(1998)
Virology
, vol.246
, pp. 179-189
-
-
Warner, M.S.1
Geraghty, R.J.2
Martinez, W.M.3
Montgomery, R.I.4
Whitbeck, J.C.5
Xu, R.6
-
23
-
-
78049521326
-
A double mutation in glycoprotein gB compensates for ineffective gD-dependent initiation of herpes simplex virus type 1 infection
-
Uchida H, Chan J, Goins W.F., Grandi P., Kumagai I, Cohen JB, et al. A double mutation in glycoprotein gB compensates for ineffective gD-dependent initiation of herpes simplex virus type 1 infection. J Virol 2010;84:12200-9.
-
(2010)
J Virol
, vol.84
, pp. 12200-12209
-
-
Uchida, H.1
Chan, J.2
Goins, W.F.3
Grandi, P.4
Kumagai, I.5
Cohen, J.B.6
-
24
-
-
31544468273
-
Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models
-
Terada K, Wakimoto H, Tyminski E., Chiocca EA, Saeki Y. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther 2006;13:705-14.
-
(2006)
Gene Ther
, vol.13
, pp. 705-714
-
-
Terada, K.1
Wakimoto, H.2
Tyminski, E.3
Chiocca, E.A.4
Saeki, Y.5
-
25
-
-
30344448580
-
Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication
-
Aghi M, Rabkin S, Martuza RL. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 2006;98:38-50.
-
(2006)
J Natl Cancer Inst
, vol.98
, pp. 38-50
-
-
Aghi, M.1
Rabkin, S.2
Martuza, R.L.3
-
26
-
-
76549129820
-
Drug combination studies and their synergy quantification using the chou-talalay method
-
Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
-
(2010)
Cancer Res
, vol.70
, pp. 440-446
-
-
Chou, T.C.1
-
27
-
-
57049155922
-
Preclinical versus clinical drug combination studies
-
Chou TC. Preclinical versus clinical drug combination studies. Leuk Lymphoma 2008;49:2059-80.
-
(2008)
Leuk Lymphoma
, vol.49
, pp. 2059-2080
-
-
Chou, T.C.1
-
28
-
-
33748794547
-
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
-
Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006;58:621-81.
-
(2006)
Pharmacol Rev
, vol.58
, pp. 621-681
-
-
Chou, T.C.1
-
29
-
-
0037219173
-
Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression
-
Kaur B, Brat DJ, Calkins C.C., Van Meir EG. Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. Am J Pathol 2003;162:19-27.
-
(2003)
Am J Pathol
, vol.162
, pp. 19-27
-
-
Kaur, B.1
Brat, D.J.2
Calkins, C.C.3
Van Meir, E.G.4
-
30
-
-
84897145705
-
The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis
-
RL OD
-
RL OD, McCormick A, Mukhopadhyay A., Woodhouse LC, Moat M, Grundy A, et al. The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis. PLoS ONE 2014;9:e90604.
-
(2014)
PLoS ONE
, vol.9
-
-
McCormick, A.1
Mukhopadhyay, A.2
Woodhouse, L.C.3
Moat, M.4
Grundy, A.5
-
31
-
-
0023878853
-
Coexpression of cytokeratins and vimentin in common epithelial tumours of the ovary: An immunocytochemical study of eighty-three cases
-
Viale G, Gambacorta M, Dell'Orto P, Coggi G. Coexpression of cytokeratins and vimentin in common epithelial tumours of the ovary: an immunocytochemical study of eighty-three cases. Virchows Archiv A Pathol Anat Histopathol 1988;413:91-101.
-
(1988)
Virchows Archiv a Pathol Anat Histopathol
, vol.413
, pp. 91-101
-
-
Viale, G.1
Gambacorta, M.2
Dell'Orto, P.3
Coggi, G.4
-
32
-
-
0023160633
-
Malignant mixed mullerian tumors. An ultrastructural and immunohistochemical analysis with histogenetic considerations
-
Geisinger KR, Dabbs DJ, Marshall RB. Malignant mixed mullerian tumors. An ultrastructural and immunohistochemical analysis with histogenetic considerations. Cancer 1987;59:1781-90.
-
(1987)
Cancer
, vol.59
, pp. 1781-1790
-
-
Geisinger, K.R.1
Dabbs, D.J.2
Marshall, R.B.3
-
33
-
-
84888024411
-
Phenotypic modifications in ovarian cancer stem cells following paclitaxel treatment
-
Craveiro V, Yang-Hartwich Y, Holmberg J.C., Sumi NJ, Pizzonia J, Griffin B, et al. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Med 2013;2:751-62.
-
(2013)
Cancer Med
, vol.2
, pp. 751-762
-
-
Craveiro, V.1
Yang-Hartwich, Y.2
Holmberg, J.C.3
Sumi, N.J.4
Pizzonia, J.5
Griffin, B.6
-
34
-
-
34447345507
-
Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients
-
Shepherd TG, Theriault BL, Campbell E.J., Nachtigal MW. Primary culture of ovarian surface epithelial cells and ascites-derived ovarian cancer cells from patients. Nat Protoc 2006;1:2643-9.
-
(2006)
Nat Protoc
, vol.1
, pp. 2643-2649
-
-
Shepherd, T.G.1
Theriault, B.L.2
Campbell, E.J.3
Nachtigal, M.W.4
-
36
-
-
0034991897
-
Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome
-
Saeki Y, Fraefel C, Ichika Wat., Breakefield XO, Chiocca EA. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther 2001;3:591-601.
-
(2001)
Mol Ther
, vol.3
, pp. 591-601
-
-
Saeki, Y.1
Fraefel, C.2
Ichika, W.A.T.3
Breakefield, X.O.4
Chiocca, E.A.5
-
37
-
-
84880291315
-
Evaluating cell lines as tumour models by comparison of genomic profiles
-
Domcke S, Sinha R, Levine D.A., Sander C., Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 2013;4:2126.
-
(2013)
Nat Commun
, vol.4
, pp. 2126
-
-
Domcke, S.1
Sinha, R.2
Levine, D.A.3
Sander, C.4
Schultz, N.5
-
39
-
-
82555189374
-
Enhanced antitumor efficacy of low-dose etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts
-
Cheema TA, Kanai R, Kim GW, Wakimoto H, Passer B, Rabkin SD, et al. Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin Cancer Res 2011;17:7383-93.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 7383-7393
-
-
Cheema, T.A.1
Kanai, R.2
Kim, G.W.3
Wakimoto, H.4
Passer, B.5
Rabkin, S.D.6
-
40
-
-
79957881687
-
A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells
-
Kanai R, Wakimoto H, Martuza R.L., Rabkin SD. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res 2011;17:3686-96.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 3686-3696
-
-
Kanai, R.1
Wakimoto, H.2
Martuza, R.L.3
Rabkin, S.D.4
-
41
-
-
84887116567
-
DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas
-
Okemoto K, Kasai K, Wagner B., Haseley A, Meisen H, Bolyard C., et al. DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas. Clin Cancer Res 2013;19:5952-9.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 5952-5959
-
-
Okemoto, K.1
Kasai, K.2
Wagner, B.3
Haseley, A.4
Meisen, H.5
Bolyard, C.6
-
42
-
-
20844452068
-
Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma
-
Benencia F, Courreges MC, Conejo-Garcia JR, Buckanovich R.J., Zhang L., Carroll RH, et al. Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. Hum Gene Ther 2005;16:765-78.
-
(2005)
Hum Gene Ther
, vol.16
, pp. 765-778
-
-
Benencia, F.1
Courreges, M.C.2
Conejo-Garcia, J.R.3
Buckanovich, R.J.4
Zhang, L.5
Carroll, R.H.6
-
43
-
-
0141757472
-
Oncolytic viral therapy for human ovarian cancer using a novel replication-competent herpes simplex virus type I mutant in a mouse model
-
Nawa A, Nozawa N, Goshima F., Nagasaka T, Kikkawa F, Niwa Y., et al. Oncolytic viral therapy for human ovarian cancer using a novel replication-competent herpes simplex virus type I mutant in a mouse model. Gynecol Oncol 2003;91:81-8.
-
(2003)
Gynecol Oncol
, vol.91
, pp. 81-88
-
-
Nawa, A.1
Nozawa, N.2
Goshima, F.3
Nagasaka, T.4
Kikkawa, F.5
Niwa, Y.6
-
44
-
-
0038492868
-
Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms
-
Nakamori M, Fu X, Meng F., Jin A, Tao L, Bast RC Jr, et al. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. Clin Cancer Res 2003;9:2727-33.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 2727-2733
-
-
Nakamori, M.1
Fu, X.2
Meng, F.3
Jin, A.4
Tao, L.5
Bast, R.C.6
-
45
-
-
33746190699
-
Functional genomic analysis of herpes simplex virus type 1 counteraction of the host innate response
-
Pasieka TJ, Baas T, Carter V.S., Proll SC, Katze MG, Leib DA. Functional genomic analysis of herpes simplex virus type 1 counteraction of the host innate response. J Virol 2006;80:7600-12.
-
(2006)
J Virol
, vol.80
, pp. 7600-7612
-
-
Pasieka, T.J.1
Baas, T.2
Carter, V.S.3
Proll, S.C.4
Katze, M.G.5
Leib, D.A.6
-
46
-
-
36048964024
-
Analysis of the role of autophagy in replication of herpes simplex virus in cell culture
-
Alexander DE, Ward SL, Mizushima N, Levine B., Leib DA. Analysis of the role of autophagy in replication of herpes simplex virus in cell culture. J Virol 2007;81:12128-34.
-
(2007)
J Virol
, vol.81
, pp. 12128-12134
-
-
Alexander, D.E.1
Ward, S.L.2
Mizushima, N.3
Levine, B.4
Leib, D.A.5
-
47
-
-
0042530129
-
The herpes simplex virus (HSV) protein ICP34.5 is a virion component that forms a DNA-binding complex with proliferating cell nuclear antigen and HSV replication proteins
-
Harland J, Dunn P, Cameron E., Conner J, Brown SM. The herpes simplex virus (HSV) protein ICP34.5 is a virion component that forms a DNA-binding complex with proliferating cell nuclear antigen and HSV replication proteins. J Neurovirol 2003;9:477-88.
-
(2003)
J Neurovirol
, vol.9
, pp. 477-488
-
-
Harland, J.1
Dunn, P.2
Cameron, E.3
Conner, J.4
Brown, S.M.5
-
48
-
-
0030993282
-
Herpes simplex virus virulence: The functions of the gamma (1)34.5 gene
-
Roizman B, Markovitz N. Herpes simplex virus virulence: the functions of the gamma (1)34.5 gene. J Neurovirol 1997;3 Suppl 1:S1-2.
-
(1997)
J Neurovirol
, Issue.3
, pp. S1-2
-
-
Roizman, B.1
Markovitz, N.2
-
49
-
-
12944272092
-
Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma
-
Rampling R, Cruickshank G, Papanastassiou V., Nicoll J, Hadley D, Brennan D., et al Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000;7:859-66.
-
(2000)
Gene Ther
, vol.7
, pp. 859-866
-
-
Rampling, R.1
Cruickshank, G.2
Papanastassiou, V.3
Nicoll, J.4
Hadley, D.5
Brennan, D.6
-
50
-
-
84855486345
-
Oncolytic virus-mediated manipulation of DNA damage responses: Synergy with chemotherapy in killing glioblastoma stem cells
-
Kanai R, Rabkin SD, Yip S, Sgubin D., Zaupa CM, Hirose Y, et al. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst 2012;104:42-55.
-
(2012)
J Natl Cancer Inst
, vol.104
, pp. 42-55
-
-
Kanai, R.1
Rabkin, S.D.2
Yip, S.3
Sgubin, D.4
Zaupa, C.M.5
Hirose, Y.6
-
52
-
-
84869868723
-
Doxorubicin-enriched, ALDH(br) mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1
-
Zhuang X, Zhang W, Chen Y., Han X, Li J, Zhang Y., et al. Doxorubicin-enriched, ALDH(br) mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1. BMC Cancer 2012;12:549.
-
(2012)
BMC Cancer
, vol.12
, pp. 549
-
-
Zhuang, X.1
Zhang, W.2
Chen, Y.3
Han, X.4
Li, J.5
Zhang, Y.6
-
53
-
-
84864681748
-
Nestin and other putative cancer stem cell markers in pancreatic cancer
-
Matsuda Y, Kure S, Ishiwata T. Nestin and other putative cancer stem cell markers in pancreatic cancer. Med Mol Morphol 2012;45:59-65.
-
(2012)
Med Mol Morphol
, vol.45
, pp. 59-65
-
-
Matsuda, Y.1
Kure, S.2
Ishiwata, T.3
-
54
-
-
80053963249
-
ABT-898 induces tumor regression and prolongs survival in a mouse model of epithelial ovarian cancer
-
Campbell N, Greenaway J, Henkin J., Petrik J. ABT-898 induces tumor regression and prolongs survival in a mouse model of epithelial ovarian cancer. Mol Cancer Ther 2011;10:1876-85.
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 1876-1885
-
-
Campbell, N.1
Greenaway, J.2
Henkin, J.3
Petrik, J.4
-
55
-
-
58149521990
-
ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer
-
Greenaway J, Henkin J, Lawler J., Moorehead R, Petrik J. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther 2009;8:64-74.
-
(2009)
Mol Cancer Ther
, vol.8
, pp. 64-74
-
-
Greenaway, J.1
Henkin, J.2
Lawler, J.3
Moorehead, R.4
Petrik, J.5
-
56
-
-
57149111052
-
Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma
-
Baker LH, Rowinsky EK, Mendelson D, Humerickhouse R.A., Knight RA, Qian J, et al. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol 2008;26:5583-8.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5583-5588
-
-
Baker, L.H.1
Rowinsky, E.K.2
Mendelson, D.3
Humerickhouse, R.A.4
Knight, R.A.5
Qian, J.6
-
57
-
-
36749060830
-
Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma
-
Ebbinghaus S, Hussain M, Tannir N., Gordon M, Desai AA, Knight R.A., et al. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res 2007;13(22 Pt 1):6689-95.
-
(2007)
Clin Cancer Res
, vol.13
, Issue.22
, pp. 6689-6695
-
-
Ebbinghaus, S.1
Hussain, M.2
Tannir, N.3
Gordon, M.4
Desai, A.A.5
Knight, R.A.6
-
58
-
-
32544450163
-
Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma
-
Adusumilli PS, Chan MK, Chun Y.S., Hezel M., Chou TC, Rusch VW, et al. Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biol Ther 2006;5:48-53.
-
(2006)
Cancer Biol Ther
, vol.5
, pp. 48-53
-
-
Adusumilli, P.S.1
Chan, M.K.2
Chun, Y.S.3
Hezel, M.4
Chou, T.C.5
Rusch, V.W.6
-
59
-
-
6944239051
-
Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207)
-
Bennett JJ, Adusumilli P, Petrowsky H., Burt BM, Roberts G, Delman KA, et al. Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J 2004;18:1001-3.
-
(2004)
FASEB J
, vol.18
, pp. 1001-1003
-
-
Bennett, J.J.1
Adusumilli, P.2
Petrowsky, H.3
Burt, B.M.4
Roberts, G.5
Delman, K.A.6
-
60
-
-
58849117217
-
Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus
-
Mahller YY, Williams JP, Baird W.H., Mitton B., Grossheim J, Saeki Y, et al. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS ONE 2009;4:e4235.
-
(2009)
PLoS ONE
, vol.4
-
-
Mahller, Y.Y.1
Williams, J.P.2
Baird, W.H.3
Mitton, B.4
Grossheim, J.5
Saeki, Y.6
-
61
-
-
0033544902
-
Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer
-
Toyoizumi T, Mick R, Abbas A.E., Kang EH, Kaiser LR, Molnar-Kimber KL. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther 1999;10:3013-29.
-
(1999)
Hum Gene Ther
, vol.10
, pp. 3013-3029
-
-
Toyoizumi, T.1
Mick, R.2
Abbas, A.E.3
Kang, E.H.4
Kaiser, L.R.5
Molnar-Kimber, K.L.6
|